479 related articles for article (PubMed ID: 29086689)
1. Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
Santibanez JF; Krstic J
Curr Protein Pept Sci; 2018; 19(12):1155-1163. PubMed ID: 29086689
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-β, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition.
Santibanez JF; Obradović H; Kukolj T; Krstić J
Dev Dyn; 2018 Mar; 247(3):382-395. PubMed ID: 28722327
[TBL] [Abstract][Full Text] [Related]
3. Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: potential use of their interplay in tumorigenesis.
Krstic J; Maslovaric I; Santibanez JF
Recent Pat Anticancer Drug Discov; 2014; 9(3):354-71. PubMed ID: 24827562
[TBL] [Abstract][Full Text] [Related]
4. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
5. Urokinase Type Plasminogen Activator and the Molecular Mechanisms of its Regulation in Cancer.
Santibanez JF
Protein Pept Lett; 2017; 24(10):936-946. PubMed ID: 28820062
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.
Santibanez JF
ISRN Dermatol; 2013; 2013():597927. PubMed ID: 23984088
[TBL] [Abstract][Full Text] [Related]
7. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
Falcone DJ; McCaffrey TA; Mathew J; McAdam K; Borth W
J Cell Physiol; 1995 Aug; 164(2):334-43. PubMed ID: 7622580
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
[TBL] [Abstract][Full Text] [Related]
9. Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.
Shiou SR; Datta PK; Dhawan P; Law BK; Yingling JM; Dixon DA; Beauchamp RD
J Biol Chem; 2006 Nov; 281(45):33971-81. PubMed ID: 16959768
[TBL] [Abstract][Full Text] [Related]
10. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Arnoletti JP; Albo D; Granick MS; Solomon MP; Castiglioni A; Rothman VL; Tuszynski GP
Cancer; 1995 Sep; 76(6):998-1005. PubMed ID: 8625226
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta differently regulates urokinase type plasminogen activator and matrix metalloproteinase-9 expression in mouse macrophages; analysis of intracellular signal transduction.
Mojsilović SS; Santibanez JF
Cell Biol Int; 2015 May; 39(5):619-28. PubMed ID: 25597879
[TBL] [Abstract][Full Text] [Related]
12. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Friess H; Duarte R; Kleeff J; Fukuda A; Tang WH; Graber H; Schilling M; Zimmermann A; Korc M; Büchler MW
Surgery; 1998 Jul; 124(1):79-86. PubMed ID: 9663255
[TBL] [Abstract][Full Text] [Related]
13. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
14. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor.
Falcone DJ; McCaffrey TA; Haimovitz-Friedman A; Garcia M
J Cell Physiol; 1993 Jun; 155(3):595-605. PubMed ID: 7684044
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel inhibits transforming growth factor-β-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration.
Mojsilovic S; Tosic M; Mojsilovic S; Zivanovic M; Bjelica S; Srdic Rajic T; F Santibanez J
J BUON; 2020; 25(2):1257-1265. PubMed ID: 32521934
[TBL] [Abstract][Full Text] [Related]
17. Urokinase induces receptor mediated brain tumor cell migration and invasion.
MacDonald TJ; DeClerck YA; Laug WE
J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Suzuki M; Kobayashi H; Kanayama N; Saga Y; Suzuki M; Lin CY; Dickson RB; Terao T
J Biol Chem; 2004 Apr; 279(15):14899-908. PubMed ID: 14747469
[TBL] [Abstract][Full Text] [Related]
19. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells.
Sieuwerts AM; Klijn JG; Henzen-Logmand SC; Bouwman I; Van Roozendaal KE; Peters HA; Setyono-Han B; Foekens JA
Int J Cancer; 1998 Jun; 76(6):829-35. PubMed ID: 9626349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
